Notably, compared to nonmalignant transformed hepatocytes, OCT1 is downregulated in HCC, which has been explained by hypermethylation of the SLC22A1 promotor region, and in vivo models showed that downregulation is linked to decreased sorafenib uptake in the tumor [32,33]. The gene discussed is SLC22A1; the disease is hepatocellular carcinoma.